Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Extragonadal germ cell tumor
Results 1-25 of 46 for your search:
Start Over
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Status: Active
Phase: Phase III
Type: Treatment
Age: 14 and over
Trial IDs: A031102, NCI-2014-01696, 1407-GUCG, 2014-003930-17, PA031102_A01PAMDREVW01, NCT02375204
Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors
Status: Active
Phase: Phase III
Type: Treatment
Age: 0 to 49
Trial IDs: AGCT1531, NCI-2017-00178, NCT03067181
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients with Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 30
Trial IDs: IRB00005056, NCI-2013-00790, 5056, MR00042551, OHSU-5056, NCT00983398
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Vaccine Therapy and Iscomatrix with or without Cyclophosphamide and Celecoxib in Treating Patients with Thoracic Malignancies or Tumors That Have Spread to the Chest Cavity
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0053, NCI-2014-02465, 140053, 348360, P131392, NCT02054104
Oral TRK Inhibitor LOXO-101 (Larotrectinib) for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 month to 21 years
Trial IDs: LOXO-TRK-15003, NCI-2016-00678, NCT02637687
Gemcitabine Hydrochloride, Oxaliplatin, and Paclitaxel in Treating Patients With Refractory Germ Cell Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 16 and over
Trial IDs: 4T-03-1, NCI-2011-01350, NCT00183820
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 10 to 69
Trial IDs: MT2005-21, NCI-2010-01700, 2006LS032, UMN-2006LS032, UMN-MT2005-21, UMN-0608M90586, NCT00432094
High-Dose Chemotherapy, Bevacizumab, and Stem Cell Transplant in Treating Patients with Recurrent Germ Cell Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 12 to 65
Trial IDs: 2008-0378, NCI-2011-01631, NCT00936936
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients with Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
Status: Temporarily closed
Phase: Phase II
Type: Supportive care, Treatment
Age: 3 to 21
Trial IDs: ACNS1123, NCI-2012-01967, CDR0000734032, COG-ACNS1123, NCT01602666
Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: IUCRO-0403, NCI-2013-00510, 1301010501, NCT01808534
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117019, NCI-2014-00802, NCT02034110
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PM1183-B-005-14, NCI-2015-01172, NCT02454972
Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Recurrent or Progressive Germ Cell Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: CCI-09-00196, NCI-2013-01195, NCT01270742
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1609, NCI-2016-01041, NCT02834013
P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Status: Active
Phase: Phase II
Type: Diagnostic
Age: 18 and over
Trial IDs: GDX-44-004, NCI-2016-01273, NCT02633501
Cabozantinib-S-Malate in Treating Younger Patients with Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 2 to 30
Trial IDs: ADVL1622, NCI-2016-01258, NCT02867592
Brentuximab Vedotin in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: IUSCC-0568, NCI-2017-00271, NCT02689219
Pembrolizumab in Treating Patients with Incurable Metastatic, Recurrent, or Platinum Refractory Germ Cell Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HCRN GU14-206, NCI-2017-00469, NCT02499952
Brentuximab Vedotin and Bevacizumab in Treating Patients with Recurrent and Refractory CD-30 Positive Germ Cell Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2015LS190, NCI-2017-01038, NCT02988843
Durvalumab and Tremelimumab in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 17-160, NCI-2017-01093, NCT03158064
Start Over